The sentinel lymph node spread determines quantitatively melanoma seeding to non-sentinel lymph nodes and survival
Anja Ulmer(University of Tübingen), Christoph A. Klein(University Hospital Regensburg), Philipp Renner(Robert Bosch Hospital), Claudia Schulz(University of Veterinary Medicine Hannover, Foundation), Gerhard Fierlbeck(Humboldt-Universität zu Berlin), Florian Weber(University of Augsburg), Melanie Werner‐Klein(University Hospital Regensburg), Klaus Dietz(University of Tübingen), Helmut Breuninger(Universitätsklinikum Tübingen), Claus Garbe(University of Tübingen), Martin Röcken(German Cancer Research Center), Hans‐Martin Häfner(University of Tübingen)
Cited by 14
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
|New England Journal of Medicine|2019|1.4k
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
|Journal of Clinical Oncology|2000|1.3k